Anshika Jain
Modern medicine has always relied on measurable biological signals. Blood glucose, cholesterol, blood pressure, hormone concentrations, inflammatory proteins, genetic variants and imaging findings can provide valuable information about what is happening inside the human body. These measurements, commonly referred to as biomarkers, have transformed diagnosis, disease monitoring and risk assessment. Yet human biology is considerably more complex than any individual measurement can capture.
A single biomarker generally represents one biological feature at one point in time. It may indicate inflammation, metabolic dysfunction, tissue damage, hormonal activity or another physiological process, but it rarely describes the entire state of an individual. A normal measurement does not necessarily mean that every biological system is functioning optimally, while an abnormal measurement may reflect temporary variation rather than persistent disease.
This limitation is driving interest in a broader concept: the biological signature. Instead of relying on one molecule or one clinical measurement, a biological signature can combine multiple interacting signals to describe a more complex physiological state. These signals may come from genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome data, clinical records, imaging, wearable sensors and environmental exposures.
The transition from biomarkers to biological signatures represents more than an increase in the number of tests. It reflects a conceptual shift in how human health is measured. Rather than searching for a single molecule that explains a disease, researchers are increasingly asking whether combinations of biological signals can provide a more comprehensive representation of health, aging, resilience, disease risk and individual physiological change.
Recent advances in artificial intelligence and multi-omics are accelerating this transition. A 2026 Nature Reviews Genetics review describes how AI can integrate genomic information with longitudinal electronic health records containing diagnoses, laboratory results, procedures and outcomes, creating new opportunities for biomarker discovery and disease-risk prediction.
The Limits of the Single Biomarker
The power of biomarkers comes partly from their simplicity. A clinician can measure a specific molecule and compare its value with established reference ranges. This makes biomarkers practical for routine healthcare.
However, simplicity can also become a limitation. Human physiology is the product of thousands of interacting processes. A single biomarker may represent only one component of a much larger biological network.
Consider inflammation. Measuring one inflammatory molecule can provide useful information, but inflammation involves multiple immune pathways, cellular interactions and signalling molecules. Similarly, blood glucose provides an important measure of metabolic status, but metabolism also depends on insulin signalling, lipid metabolism, mitochondrial activity, liver function, muscle physiology, diet and other factors.
A biomarker can therefore be highly informative without being comprehensive.
The challenge becomes even greater when researchers attempt to predict future health. A single measurement taken today may not reveal whether a biological process is stable, improving or deteriorating. Repeated measurements and combinations of signals can potentially provide a richer picture of biological change.
This is one reason the concept of biological signatures has become increasingly important. A signature does not necessarily replace individual biomarkers. Instead, it places them into a broader biological context.
What Is a Biological Signature?
A biological signature can be understood as a reproducible pattern involving multiple biological measurements that is associated with a particular physiological state, disease process, exposure, response or health trajectory.
The components of a signature can vary depending on the scientific question. A cancer signature may combine genetic alterations, proteins and circulating molecules. An aging signature may integrate epigenetic, proteomic and metabolic measurements. A cardiovascular signature may combine clinical variables with proteins, metabolites and genomic information.
The essential difference is that the interpretation comes from the pattern rather than from one measurement.
This concept is closely connected to multi-omics. Genomics examines DNA, transcriptomics studies RNA activity, proteomics examines proteins, and metabolomics captures small molecules produced through cellular processes. Each layer provides a different view of biology.
When these layers are integrated, researchers can potentially observe relationships between genetic predisposition, gene activity, protein function and metabolism.
A 2026 Nature Genetics perspective on clinical implementation of multi-omics argues that multi-omics can provide holistic insights across interacting molecular layers, while also highlighting the substantial challenges of standardisation, interpretation, reproducibility and clinical validity.
The biological signature is therefore not simply “more data.” It is an attempt to extract meaningful biological structure from interconnected data.
From Molecular Snapshots to Biological Patterns
One of the most important advantages of biological signatures is the possibility of moving beyond snapshots.
Traditional laboratory testing often provides a measurement from a particular day. That measurement may be clinically useful, but biological systems change continuously.
A person’s metabolism changes after eating, during exercise and during periods of illness. Hormonal levels fluctuate throughout the day. Immune activity responds to infections and environmental challenges. Microbial communities respond to diet and medications. Protein and metabolite concentrations can change in response to physiological stress.
A biological signature can potentially incorporate these measurements across time, allowing researchers to distinguish temporary variation from persistent patterns.
This creates the possibility of studying health as a trajectory rather than a static state. Instead of asking whether one biomarker is abnormal, researchers can ask whether a collection of biological signals is changing together in a meaningful direction.
This approach is particularly relevant to aging. Biological aging is not represented by a single process. It involves changes in molecular regulation, metabolism, inflammation, cellular function and tissue maintenance.
Recent research into biological-age clocks demonstrates how multiple molecular measurements can be combined to estimate aspects of biological aging. The 2026 OMICmAge study integrated multi-omics with electronic medical records and developed models of biological age using data from approximately 31,000 participants in the Mass General Brigham Biobank.
Multi-Omics and the Architecture of Health
Multi-omics provides one of the strongest foundations for developing biological signatures. Genomic information provides relatively stable information about inherited variation. Epigenomic measurements can reflect regulatory states influenced by biological and environmental processes. Transcriptomics captures patterns of gene expression. Proteomics describes proteins involved in cellular functions and signalling. Metabolomics reflects downstream biochemical activity.
Each layer represents a different level of biological organisation. This means that two individuals with similar genetic risk may still have different physiological states because their gene regulation, protein activity or metabolism differs. Conversely, individuals with different genetic backgrounds may share similar biological states. This is one reason multi-omics signatures can potentially provide more individualised information than genomic information alone.
A 2026 Nature Communications study involving 23,776 UK Biobank participants found that adding metabolomic and proteomic information improved prediction across 17 incident diseases compared with clinical predictors alone. The study also found that the predictive contribution of different omics layers varied by disease. The finding illustrates an important principle: there may not be one universal biological signature of health. Different physiological processes may require different combinations of measurements.
Proteins and Metabolites as Windows Into Current Physiology
Among the various molecular layers, proteomics and metabolomics are particularly interesting because they can provide information closer to current physiological activity.
Genes provide instructions, but proteins perform many of the body’s functions. Metabolites represent products and intermediates of biochemical processes. Changes in these molecules can therefore provide clues about what cells and tissues are doing at a particular time.
A 2026 perspective in Nature describes metabolomics as an increasingly powerful way of studying metabolism across scales, from individual cells to population-level studies. Population-scale metabolomics can help identify molecular patterns associated with disease, environmental exposures and genetic variation, while single-cell metabolomics can reveal heterogeneity within tissues.
This creates an opportunity for biological signatures that are more closely connected to active physiology.
Instead of asking only what genetic risk a person carries, researchers can potentially examine how that risk is being expressed through current molecular and metabolic states.
Biological Age as a Composite Signature
Biological age is one of the clearest examples of the move from isolated biomarkers toward composite signatures.
Chronological age is straightforward: it measures the amount of time since birth. Biological aging, however, involves multiple processes occurring at different rates across individuals.
Researchers have therefore developed biological-age clocks based on molecular and physiological measurements. Some use DNA methylation, while others incorporate proteins, metabolites or clinical variables.
Recent research is expanding these models. A 2026 study introduced StackAge, an ensemble-based biological-age model integrating plasma proteomic and metabolomic data from more than 30,000 UK Biobank participants. The researchers reported that estimated aging rates provided additional information for predicting several chronic diseases beyond conventional omics and demographic features.
Another 2026 conceptual framework has proposed organ-specific aging clocks based on multi-omics signatures, recognising that different organs may age at different rates.
These approaches highlight an important development. Instead of asking for one number that represents a person’s biological age, future systems may describe multiple biological dimensions and organ-specific trajectories.
The Microbiome Adds Another Biological Layer
Human health signatures are also expanding beyond human cells.
The microbiome contains microbial communities that interact with metabolism, immunity and host physiology. Microorganisms produce metabolites and other molecules that can influence biological processes throughout the body.
This makes microbiome information a potentially important component of comprehensive health signatures.
However, microbiome signatures are particularly complex because microbial composition and activity can change with diet, medications, geography, age and other environmental conditions. The presence of a particular microbial species does not necessarily tell researchers what that organism is doing.
Modern microbiome research is therefore increasingly integrating genomic, transcriptomic, proteomic and metabolomic measurements. A 2026 Nature Microbiology review notes that multi-omic integration has substantial potential for understanding host–microbiome interactions but remains analytically and computationally challenging.
A September 2026 Nature Communications perspective similarly emphasises that integrating multiple omics layers can help reveal microbial functions, interactions and dynamics rather than merely cataloguing which organisms are present.
This suggests that future health signatures may incorporate not only human molecular information but also information about the biological ecosystem living alongside the human host.
Environmental Exposure and the Exposome
A truly comprehensive biological signature may also need to include what happens outside the body.
The exposome refers broadly to the collection of environmental and lifestyle exposures experienced throughout life. These can include diet, pollutants, infections, medications, physical conditions and other non-genetic influences.
The relevance of the exposome becomes clearer when considering why people with similar biological characteristics can develop different health outcomes.
Environmental exposure can influence molecular pathways, immune responses, metabolism and microbial communities. These effects can potentially become visible through changes in proteins, metabolites, gene regulation and other biological measurements.
A 2026 Nature Medicine study created an atlas of associations between exposome variables and human phenotypes, illustrating the scale of relationships that can exist between environmental exposures and health outcomes.
This creates a broader vision of the biological signature. Instead of measuring only internal biology, future health models may combine internal molecular measurements with information about external exposures.
The result could be a more contextual interpretation of health.
Non-Invasive Biomolecular Monitoring
One of the most significant developments in this field is the movement toward less invasive methods of biological measurement.
Traditional molecular testing often requires blood draws or other clinical sampling. Advances in biosensors, mass spectrometry and molecular analysis are opening possibilities for measuring biological signals in sweat, saliva, tears and interstitial fluid.
A 2026 Nature Biotechnology review describes advances in non-invasive biomolecular profiling and highlights the potential of proteomic and metabolomic measurements from non-invasive biofluids for monitoring dynamic physiological states.
This could eventually make biological signatures more longitudinal.
If reliable molecular information can be obtained without frequent clinical blood draws, researchers may be able to collect measurements repeatedly in everyday environments. That could transform biological signatures from occasional laboratory profiles into dynamic representations of physiological change.
However, accuracy, calibration and clinical validation remain essential. A convenient measurement is useful only if it reliably represents the biological process it claims to measure.
Artificial Intelligence and the Discovery of Biological Signatures
The increasing complexity of biological datasets has created an important role for artificial intelligence.
Traditional statistical approaches can identify relationships between variables, but modern health datasets may contain thousands or millions of measurements across multiple biological layers. AI and machine learning can help identify patterns within these high-dimensional datasets.
A September 2026 review in Signal Transduction and Targeted Therapy describes AI as increasingly important in biomarker discovery because it can integrate complex multimodal biomedical data. The review also emphasises that translating AI-derived biomarkers into clinical practice remains inconsistent and requires stronger validation.
This distinction is critical. AI can identify a statistical signature without necessarily explaining its biological mechanism.
A model may discover that a particular combination of proteins predicts a clinical outcome, but researchers still need to determine whether the signature is reproducible, biologically meaningful and clinically useful.
The future of biological-signature research will therefore require cooperation between computational science and experimental biology.
From Disease Signatures to Health Signatures
Much biomarker research has historically focused on identifying disease. Researchers search for molecules that distinguish cancer from healthy tissue, identify cardiovascular risk or indicate neurological disease.
An emerging question is whether similar approaches can define positive states of health.
Instead of asking only what distinguishes disease from health, researchers may investigate what characterises resilience, healthy aging, metabolic stability, recovery from stress or preserved organ function.
This is a considerably more complicated problem because “health” is not a single disease-free state. A healthy person can have temporary inflammation, variation in metabolism or changes in microbial composition without developing disease.
Health signatures may therefore need to describe system stability and adaptability rather than simply the absence of abnormal biomarkers.
This could lead to a future in which researchers identify patterns associated with resilience and healthy physiological function alongside patterns associated with disease.
The Importance of Longitudinal Biological Signatures
A biological signature becomes potentially more informative when measured repeatedly.
A single profile may describe a person’s biological state today. A sequence of profiles can show how that state is changing.
This distinction is central to predictive health. Researchers increasingly want to know whether biological aging is accelerating, whether metabolic regulation is becoming less stable, whether inflammation is persistently increasing or whether an organ-specific molecular signature is changing.
Longitudinal signatures could therefore help distinguish temporary biological fluctuations from persistent transitions.
This approach also aligns with the broader development of predictive healthcare, in which researchers increasingly combine electronic health records, molecular measurements and longitudinal data to model individual risk. AI-based integration of genomics and EHR information is one example of this expanding framework.
The future may consequently involve fewer isolated health measurements and more continuous biological trajectories.
The Challenge of Turning Signatures Into Clinical Tools
The discovery of a biological signature does not automatically make it clinically useful.
A signature must be reproducible across populations, laboratories and measurement platforms. Researchers must determine whether it performs consistently across different demographic groups and clinical contexts.
Interpretability also matters. Clinicians need to understand what a signature means and how it should influence a decision. If a model produces a complex score without an understandable relationship to clinical action, adoption may be difficult.
A 2026 Nature Genetics perspective on clinical implementation stresses that the major challenge for multi-omics is increasingly shifting from generating data to standardising, interpreting and integrating complex information into healthcare systems. It highlights interoperability, quality standards, explainable AI and multidisciplinary care as important components of clinical implementation.
Therefore, the future of biological signatures depends as much on clinical infrastructure and validation as on laboratory technology.
The Need for Population Diversity
Another challenge is that biological signatures are not automatically universal.
A model developed using one population may not perform identically in another because genetics, diet, environmental exposures, healthcare access, lifestyle and disease patterns can differ.
This issue is particularly relevant to biological-age research. Most established biological-age models have historically been developed using predominantly Western populations.
The BHARAT study in India illustrates an effort to address this gap. The 2026 study aims to develop composite signatures of aging in the Indian population by integrating multi-omics, biochemical, clinical and lifestyle information, with representation across age groups and rural and urban populations.
Such research demonstrates why population diversity matters. A biological signature intended for global health should be tested across different populations rather than assuming that one dataset can represent human biology everywhere.
Toward a Comprehensive Health Signature
The long-term goal may not be to find one universal biological signature. Instead, healthcare could develop layered signatures representing different dimensions of human health.
A health profile could eventually integrate metabolic state, immune activity, biological aging, organ-specific function, microbiome activity, genetic predisposition, environmental exposure and longitudinal clinical history.
Artificial intelligence could potentially combine these layers into dynamic models that identify patterns and changes over time.
Such a system would resemble a biological dashboard rather than a single laboratory result. One dimension could indicate metabolic stability, another could describe inflammatory activity, another could reflect biological aging, while additional layers could describe cardiovascular, neurological or immune states.
The important principle would be context. A person’s health would not be reduced to one number. Instead, multiple biological signatures could be interpreted together to create a more complete representation of physiological state.
Conclusion
The history of medicine has been strongly influenced by the discovery of individual biomarkers. These measurements remain fundamental to modern healthcare, but advances in multi-omics, artificial intelligence, microbiome research, non-invasive molecular monitoring and longitudinal health data are revealing the limitations of interpreting human biology one variable at a time.
The emerging concept of biological signatures offers a broader approach. Instead of searching for one molecule that represents health or disease, researchers can investigate combinations of genomic, epigenetic, proteomic, metabolic, microbial, clinical and environmental signals.
Recent research shows how this approach is already being applied to disease prediction, biological-age estimation, cardiovascular risk, environmental health and non-invasive physiological monitoring.
The ultimate objective is not simply to generate larger datasets or more sophisticated health scores. It is to understand human biology with greater context and precision. A meaningful biological signature should help explain what is happening, how different systems interact and how a person’s physiological state changes over time.
Medicine may therefore gradually move from the era of isolated biomarkers toward an era of integrated biological signatures. In that future, measuring health could become less about asking whether one value is normal and more about understanding the complex molecular, physiological and environmental patterns that define an individual’s state of health.